Skip to main content
. Author manuscript; available in PMC: 2018 Jan 1.
Published in final edited form as: Exp Hematol. 2009 May;37(5):533–538. doi: 10.1016/j.exphem.2009.02.001

Figure 2.

Figure 2

The effect of A2bAR activation or deletion on the release of TNF-α from macrophages. (A) TNF-α released from WT macrophages. Cells were treated with the A2bAR antagonist CVT-6883 (1 μM) and then incubated with the A2bAR agonist BAY 60-6583 (1 μM) and followed by LPS (10 μg/ml) challenge for a total of 2 hours, as described under Methods. TNF-α released from cells is shown as a ratio to the maximal TNF-α level released from vehicle-treated cells (designated as 1). Shown are averages +/- SD (n=3). (B) TNF-α released from A2bAR KO macrophages. Cells were treated as in (A). Shown are averages +/- SD (n=3). *, p < 0.05 for vehicle-treated cells as compared to BAY 60-6583-treated cells, and BAY 60-6583-treated cells as compared to BAY 60-6583 plus CVT-6883-treated cells or just CVT-6883-treated cells.